Christine Pocha

ORCID: 0000-0002-2906-1144
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Liver Disease Diagnosis and Treatment
  • Liver Disease and Transplantation
  • Hepatocellular Carcinoma Treatment and Prognosis
  • Hepatitis C virus research
  • Hepatitis B Virus Studies
  • Alcohol Consumption and Health Effects
  • Cancer-related molecular mechanisms research
  • Gallbladder and Bile Duct Disorders
  • Cancer, Lipids, and Metabolism
  • MicroRNA in disease regulation
  • Hormonal and reproductive studies
  • Genetic and Kidney Cyst Diseases
  • Ferroptosis and cancer prognosis
  • Cancer Immunotherapy and Biomarkers
  • Renal cell carcinoma treatment
  • Sexual Differentiation and Disorders
  • Economic and Financial Impacts of Cancer
  • Vascular anomalies and interventions
  • Bartonella species infections research
  • Biliary and Gastrointestinal Fistulas
  • Organ Donation and Transplantation
  • Drug-Induced Hepatotoxicity and Protection
  • Microscopic Colitis
  • Global Cancer Incidence and Screening
  • Pharmacogenetics and Drug Metabolism

Avera Health
2025

University of South Dakota
2017-2024

Avera McKennan Hospital & University Health Center
2021-2023

University Medical Center
2019-2022

Thomas Jefferson University
2019

University of Sioux Falls
2017

Minneapolis VA Health Care System
2010-2016

University of Bern
2015-2016

Minneapolis VA Medical Center
2010-2016

University of Minnesota
2010-2014

Background Guidelines recommend screening for hepatocellular cancer (HCC) with ultrasonography. The performance of ultrasonography varies widely. Computed tomography (CT) is less operator dependent. Aim To compare the and cost twice-a-year to once-a-year triple-phase-contrast CT HCC in veterans. We hypothesised that detects smaller HCCs at lower overall cost. Method One hundred sixty-three subjects compensated cirrhosis were randomised biannual or yearly CT. Twice-a-year alpha-feto protein...

10.1111/apt.12370 article EN cc-by Alimentary Pharmacology & Therapeutics 2013-06-10

Hepatocellular carcinoma (HCC) is a leading cause of morbidity and mortality in cirrhosis patients. This provides an opportunity to target the highest-risk population, yet surveillance rates United States Europe range from 10% 40%. The goal this study was identify barriers HCC surveillance, using data Veterans Health Administration, largest provider liver-related health care States. We included all patients 75 years age or younger who were diagnosed with January 1, 2008, until December 31,...

10.1002/hep.28765 article EN Hepatology 2016-08-17

The preoperative selection of patients with intermediate-stage hepatocellular carcinoma (HCC) who are likely to have an objective response first transarterial chemoembolization (TACE) remains challenging.To develop and validate a clinical-radiomic model (CR model) for preoperatively predicting treatment TACE in HCC.A total 595 HCC were included this retrospective study. A tumoral peritumoral (10 mm) radiomic signature (TPR-signature) was constructed based on 3,404 features from 4 regions...

10.1159/000512028 article EN cc-by-nc-nd Liver Cancer 2021-01-01

Chronic hepatitis C virus (HCV) infection affects approximately 1.3% of the United States population and 4% veterans who use Department Veterans Affairs medical services. HCV is primary cause cirrhosis, hepatocellular carcinoma (HCC), end-stage liver disease requiring transplantation in States. Management chronic aimed at halting progression, preventing cirrhosis decompensation, reducing risk HCC, treating extrahepatic complications infection. As part a comprehensive management strategy,...

10.1038/ajg.2012.48 article EN The American Journal of Gastroenterology 2012-04-24

The alfapump system has been shown to be a possible alternative repeat therapeutic paracentesis (TP) in select patients with refractory ascites (RA) Aim: To assess the safety and efficacy of on control quality life these Methods: Patients cirrhosis RA requiring ≥2 TPs 30 days prior were enrolled followed for 24 months (M) post-implant. Primary endpoint assessed at 6M was reduction requirement; end point device related adverse events resulting intervention, explant, or death Results: 40 RA,...

10.14309/ajg.0000000000003300 article EN The American Journal of Gastroenterology 2025-01-06

Six Sigma and Lean Thinking are quality initiatives initially deployed in industry to improve operational efficiency leading better subsequent cost savings. The financial rationale for embarking on this journey is clear; applying it today's health care remains challenging. of medical increasing at an alarming rate; most these increases attributed aging population technological advances; therefore, largely beyond control. Furthermore, caused by unnecessary inefficiency associated with the...

10.1097/qmh.0b013e3181fa0783 article EN Quality Management in Health Care 2010-10-01

Abstract Aims To determine the efficacy of motivational enhancement therapy (MET ) on alcohol use in patients with hepatitis C virus ( HCV and an disorder AUD ). Design Randomized, single‐blind, controlled trial comparing MET to a control education condition 6‐month follow‐up. Setting Patients were recruited from clinics at M inneapolis, innesota P ortland, O regon V eterans A ffairs H ealth are S ystems, USA . Participants Intervention , continued n = 139) randomized receive either 70) or...

10.1111/add.12679 article EN Addiction 2014-07-08

The Child–Turcotte–Pugh (CTP) score is a widely used and validated predictor of long-term survival in cirrhosis. However, the cutpoints for stratifying laboratory variables CTP have never been validated. objective this study was to identify evidence-based subscores improve its predictive capacity transplant-free survival. Retrospective observational study. Using cohort 30,897 cirrhotic US Veteran patients with at least 5 years follow-up, we performed Cox proportional hazard model iterations...

10.1007/s10620-016-4239-6 article EN cc-by-nc Digestive Diseases and Sciences 2016-07-12

The regulation of cancer stem cells (CSCs) is influenced by RNA-binding proteins (RBPs). present study sought to investigate the role NOVA2 in processes self-renewal, carcinogenesis, and lenvatinib resistance liver CSCs.

10.21037/jgo-24-145 article EN Journal of Gastrointestinal Oncology 2024-08-01

Background: At present, there are no definitive optimal treatment options for patients with hepatocellular carcinoma (HCC) following first-line failure. To maximize the survival benefit of patients, we compared combination therapy regorafenib and programmed death-1 (PD-1) inhibitors monotherapy as a second-line advanced HCC. Methods: Our multicenter retrospective study evaluated consecutive HCC who received plus PD-1 or alone later-line from May 2019 to January 2022. The primary endpoint was...

10.21037/atm-22-6614 article EN Annals of Translational Medicine 2023-01-01

Circular RNAs (circRNAs) are important for the process of cancer initiation and progression. However, role circRNAs in hepatocellular carcinoma (HCC) remains incompletely understood. Therefore, we further explored expression network HCC.Whole-transcriptome microarrays HCC paired normal liver tissues were obtained from Gene Expression Omnibus (GEO) database. The structures tumor-associated acquired by Cancer-Specific CircRNA Database (CSCD). StarBase, circBank, R packages (miRNAtap multiMiR)...

10.21037/atm-22-3147 article EN Annals of Translational Medicine 2022-07-01

Hepatocellular carcinoma (HCC) constitutes approximately 75-85% of primary liver cancers and is a heavy burden on public health. Many innovative prediction systems have integrated radiomics, artificial intelligence, pathological information, or even genetic information for the stratification prognosis patients with HCC. However, these still lack practical clinical applications. Classical HCC staging remain mainstream tool treatment efficacy to date; although, variable characteristics...

10.21037/jgo-2024-850 article EN Journal of Gastrointestinal Oncology 2024-12-01

Article AbstractBackground and Aims: Selective serotonin reuptake inhibitors (SSRIs) are commonly prescribed for patients with chronic hepatitis C virus (HCV) infection. Research suggests that promotes the development growth of hepatocellular carcinoma (HCC). We tested hypothesis whether exposure to SSRIs is associated an increased risk HCC in HCV patients.Method: Patients who entered United States Veterans Affairs (VA) Hepatitis Clinical Case Registry 2000 2009 were analyzed. During 8 years...

10.4088/jcp.13m08877 article EN The Journal of Clinical Psychiatry 2014-10-28

Letters21 August 2012Screening for Liver Cancer: The Rush to JudgmentFrank A. Lederle, MD and Christine Pocha, MD, PhDFrank MDFrom Minneapolis Veterans Affairs Medical Center, Minneapolis, MN 55417.Search more papers by this author PhDFrom authorAuthor, Article, Disclosure Informationhttps://doi.org/10.7326/0003-4819-157-4-201208210-00022 SectionsAboutFull TextPDF ToolsAdd favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:We agree with...

10.7326/0003-4819-157-4-201208210-00022 article EN Annals of Internal Medicine 2012-08-21

In recent decades, gut microbiota have received emerging attention regarding their integral role in chronic liver disease progression, given the anatomic connection and gut–liver axis. Emerging evidence has indicated a complex link between hepatocellular carcinoma. This review explores pathophysiological crosstalk dysbiosis hepatocarcinogenesis. The metabolic immunologic effects mediated by gut-microbiota-derived metabolites, such as bile acids, short-chain fatty alcohol, could impact...

10.3390/gidisord5020013 article EN cc-by Gastrointestinal Disorders 2023-04-04
Coming Soon ...